Vitexin

Vitexin

SCHEMBL4469474

O=c1cc(-c2ccc(O)cc2)oc2c(C3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 1.00
CYP1A2 P05177 1/20 1.00
GAA P10253 5/20 0.83
KDM4E B2RXH2 5/20 0.83
POLB P06746 4/20 0.83
APEX1 P27695 4/20 0.83
TDP1 Q9NUW8 4/20 0.83
MEN1 O00255 3/20 0.83
KMT2A Q03164 3/20 0.83
ALDH1A1 P00352 3/20 0.83
MAPT P10636 2/20 0.83
THRB P10828 1/20 0.83
NTSR1 P30989 1/20 0.74
RECQL P46063 1/20 0.74
SYNJ2 O15056 1/20 0.68
AKR1B1 P15121 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.60
SLCO2B1 O94956 1/20 0.60
TNF P01375 1/20 0.60
PTPN1 P18031 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vitexin SCHEMBL29572351 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL2741236 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL10307510 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL10013309 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL25277 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL6073075 0.91 L3MBTL1 (0.82) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL30799311 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL13059270 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL29687058 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL10307494 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009024707-A2 USE OF RADAMEA MONTANA EXTRACT FOR PREPARING A COSMETIC COMPOSITION UNIVERSITE CLAUDE BERNARD LYON I (FR) 2009-02-26 WO claimed
WO-2025125504-A1 COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2025-06-19 WO disclosed
EP-4570246-A1 COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) 2025-06-18 EP disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
US-20190093096-A1 COMOSAIN AND BROMELAINS AS IMMUNO-THERAPY IN THE TREATING AND/OR PREVENTING VARIOUS TYPES OF CANCER IN A MAMMAL LIAO, ALEX BISMARK (US) 2019-03-28 US disclosed
WO-2018190783-A1 THE CLONING AND EXPRESSION OF COMOSAIN'S MINIGENE, AND AS IMMUNO-TARGET CHEMOTHERAPEUTIC AGENTS IN TREATING AND OR PREVENTING VARIOUS TYPES OF CANCER IN MAMMALS LIAO BENEDICT SCHUE (US) 2018-10-18 WO disclosed
WO-2009024707-A2 USE OF RADAMEA MONTANA EXTRACT FOR PREPARING A COSMETIC COMPOSITION UNIVERSITE CLAUDE BERNARD LYON I (FR) 2009-02-26 WO disclosed
US-20060040911-A1 Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) LIAO BENEDICT S 2006-02-23 US disclosed